A型肉毒杆菌毒素用于治疗慢性肌筋膜疼痛。

Incobotulinum toxin type A for treatment of chronic myofascial pain.

作者信息

Chaurand Jorge, Godínez-Victoria Marycarmen, Tellez-Girón Aldo, Facio-Umaña Jose-Alfredo, Jimenez-Ponce Fiacro

机构信息

Maxillofacial Surgery Department, National Medical Center "20 de Noviembre" Institute for Social Security and Services for State Workers.

Research Department, Superior School of Medicine, National Polytechnic Institute.

出版信息

J Oral Sci. 2020 Dec 23;63(1):37-40. doi: 10.2334/josnusd.20-0090. Epub 2020 Dec 9.

DOI:10.2334/josnusd.20-0090

PMID:33298638

Abstract

PURPOSE

This study assessed the effectiveness of incobotulinum toxin type A (IBTx) for chronic myofascial pain affecting the masseter and temporal muscles.

METHODS

Twenty two patients who received a diagnosis of chronic masseter and temporalis myofascial pain were evaluated by using a visual analog pain scale (VAS), digital pressure algometry, and the SF-36 Health Survey at baseline (T0), before IBTx injection. Patients were again evaluated at 2 months (T1) and 7 months (T2) after IBTx injection.

RESULTS

VAS scores for pain significantly differed (P = 0.029, Friedman test). Post-hoc tests showed a significant reduction in pain at 2 months (T0-T1) and 7 months (T0-T2) (P = 0.011 and P = 0.028, respectively; Wilcoxon test) but not between 2 and 7 months (P = 0.676; Wilcoxon test). There was no significant difference in pressure algometry values (P = 0.385, Friedman test). Quality of life (QOL) assessment showed a significant difference (P = 0.002, Friedman test). Post-hoc tests showed a significant improvement in QOLat 2 months, but no significant difference at 7 months (P = 0.004 and P = 0.260, Wilcoxon test).

CONCLUSION

IBTx injection resulted in safe, effective short-term pain relief for patients with chronic facial pain affecting the masseter and temporalis muscles.

摘要

目的

本研究评估了A型肉毒杆菌毒素（IBTx）对影响咬肌和颞肌的慢性肌筋膜疼痛的疗效。

方法

22例被诊断为慢性咬肌和颞肌肌筋膜疼痛的患者在注射IBTx前的基线期（T0），通过视觉模拟疼痛量表（VAS）、数字压力痛觉测量法和SF-36健康调查进行评估。在注射IBTx后的2个月（T1）和7个月（T2）再次对患者进行评估。

结果

疼痛的VAS评分有显著差异（P = 0.029，Friedman检验）。事后检验显示在2个月（T0-T1）和7个月（T0-T2）时疼痛显著减轻（分别为P = 0.011和P = 0.028；Wilcoxon检验），但在2个月至7个月之间无显著差异（P = 0.676；Wilcoxon检验）。压力痛觉测量值无显著差异（P = 0.385，Friedman检验）。生活质量（QOL）评估显示有显著差异（P = 0.002，Friedman检验）。事后检验显示在2个月时QOL有显著改善，但在7个月时无显著差异（P = 0.004和P = 0.260，Wilcoxon检验）。